- Home
- IMNM vs INSW Comparison
IMNM vs INSW Comparison
Compare IMNM & INSW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- INSW
- Stock Information
- Founded
- IMNM 2006
- INSW 1999
- Country
- IMNM United States
- INSW United States
- Employees
- IMNM N/A
- INSW N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- INSW Semiconductors
- Sector
- IMNM Health Care
- INSW Technology
- Exchange
- IMNM Nasdaq
- INSW Nasdaq
- Market Cap
- IMNM 747.7M
- INSW N/A
- IPO Year
- IMNM 2020
- INSW N/A
- Fundamental
- Price
- IMNM $12.68
- INSW $52.03
- Analyst Decision
- IMNM Strong Buy
- INSW Strong Buy
- Analyst Count
- IMNM 4
- INSW 3
- Target Price
- IMNM $28.75
- INSW $68.00
- AVG Volume (30 Days)
- IMNM 817.9K
- INSW 580.5K
- Earning Date
- IMNM 11-07-2024
- INSW 11-05-2024
- Dividend Yield
- IMNM N/A
- INSW 10.94%
- EPS Growth
- IMNM N/A
- INSW N/A
- EPS
- IMNM N/A
- INSW 10.49
- Revenue
- IMNM $10,784,000.00
- INSW $1,024,252,000.00
- Revenue This Year
- IMNM N/A
- INSW $0.49
- Revenue Next Year
- IMNM N/A
- INSW N/A
- P/E Ratio
- IMNM N/A
- INSW $5.07
- Revenue Growth
- IMNM 62.73
- INSW N/A
- 52 Week Low
- IMNM $6.93
- INSW $42.08
- 52 Week High
- IMNM $30.96
- INSW $65.94
- Technical
- Relative Strength Index (RSI)
- IMNM 37.57
- INSW 51.09
- Support Level
- IMNM $12.24
- INSW $50.29
- Resistance Level
- IMNM $13.40
- INSW $54.84
- Average True Range (ATR)
- IMNM 0.79
- INSW 1.06
- MACD
- IMNM -0.22
- INSW 0.21
- Stochastic Oscillator
- IMNM 13.30
- INSW 43.56
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.